F Drummond*1, C Mullin2, M Poehlman2, and SMART Protocol Team and the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA 065)
1Univ. of New South Wales, Sydney, Australia and 2Univ. of Minnesota, Minneapolis, USA
P Kumar*1, V Williams2, K Tahima3, A Rodriquez-French4, M Thompson5, P Wannamaker2, J Hernandez2, and K Pappa2
1Georgetown Univ. Med. Ctr., Washington DC, USA; 2GlaxoSmithKline, Research Triangle Park, NC, USA; 3The Miriam Hosp., Providence, RI, USA; 4San Fernando Hosp., Panama City, Panama; and 5ARCA, Atlanta, GA, USA
M Bongiovanni1, P Cicconi1, S Landonio2, P Meraviglia2, L Testa3, A Di Biagio4, M Volpi1, E Chiesa1, M Schiavini2, S Melzi1, F Tordato1, M Moroni1, T Bini1, and A d'Arminio Monforte*1
1Inst. of Infectious Diseases and Tropical Med., Univ. of Milan, Italy; 2L. Sacco Hosp., Milan, Italy; 3Busto Arsizio Hosp., Varese, Italy; and 4Clin. Infectious Diseases, Univ. of Genoa, Italy
D A Cooper*1, P Reiss2, K Henry3, M Nelson4, M O'Hearn5, P Piliero6, J Reynes7, K Arasteh8, J Chung9, D Guimaraes9, T Kinchelow9, A Bertasso9, and the TORO 1 and TORO 2 study groups
1Natl. Ctr. in HIV Epidemiology and Clin. Res., Univ. of New South Wales, Sydney, Australia; 2Academic Med. Ctr., Amsterdam, The Netherlands; 3Hennepin County Med. Ctr., Minneapolis, MN, USA; 4Chelsea and Westminster Hosp., London, UK; 5Oregon Hlth. and Sci. Univ., Portland, USA; 6Albany Med. Coll., NY, USA; 7Hosp. Gui de Chauliac, Montpellier, France; 8EPIMED c/o Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany; and 9Roche, Nutley, NJ, USA
D Podzamczer*1, E Ferrer1, P Sanchez1, J M Gatell2, M Crespo3, M Lonca2, J Sanz4, J Niubo1, S Veloso5, J M Llibre6, P Barrufet7, A Salas8, E Merino9, J Martinez-Lacasa10, L del Rio11, and ABCDE Study Team
1Hosp. Univ. de Bellvitge. L'Hospitalet, Barcelona, Spain; 2Hosp. Clin., Barcelona, Spain; 3Hosp. Vall d'Hebron. Barcelona.; 4Hosp. Principe de Asturias. Alcala de Henares. Madrid; 5Hosp. Joan XIII. Tarragona; 6Hosp. Sant Jaume de Calella. Calella; 7Hosp. de Mataro. Mataro; 8Hosp. Son Dureta. Palma de Mallorca; 9Hosp. Gen. de Alicante; 10Hosp. Mutua de Terrassa. Terrassa; and 11CETIR, Barcelona, Spain
W Powderly*1, P Cahn2, F Raffi3, M Saag4, A Shaw5, J Hinkle5, E Mondou5, J B Quinn5, and F Rousseau on behalf of the FTC-301A Study Team5
1Washington Univ. Sch. of Med., St. Louis, MO, USA; 2Fndn. Huesped, Buenos Aires, Argentina; 3CHU Nantes, France; 4Univ. of Alabama at Birmingham, USA; and 5Gilead Sci., Inc., Durham, NC, USA
R Murphy*1, C Katlama2, G-J Weverling3, F Hoff1, R Roubenoff4, B Berzins1, J Gatell5, A Horban6, A van Eeden7, F Antunes8, E Bijleveld3, B Clotet9, S Staszewski10, R van Leeuwen3, J Lange3, and Atlantic Study Team
1Northwestern Univ., Chicago, IL, USA; 2Hosp. Pitie-Salpetriere, Paris, France; 3Intl. Antiviral Therapy Evaluation Ctr., Amsterdam, The Netherlands; 4Tufts Univ., Boston, MA, USA; 5Hosp. Clin., Barcelona, Spain; 6Wojewodzki Szpital Zakazny, Warsaw, Poland; 7Jan van Goyenkliniek, Amsterdam, The Netherlands; 8Hosp. Santa Maria, Lisbon, Portugal; 9Hosp. Univ. Germans Trias I Pujol, Barcelona, Spain; and 10Klinikum der Johann Wolfgang Goethe Univ., Frankfurt, Germany
S Pujari*1,2, A Patel3, A Dravid1,4, N Gupte4, S Bhagat1, E Naik2, A Mane1, and K Patel3
1Ruby Hall Clin., Pune, India; 2Univ. of South Florida, Tampa, USA; 3Sterling Hosp., Ahmedabad, India; and 4Pune, India
S L Walmsley*1, J Benetucci2, A Brutus3, N Clumek4, U B Dragsted5, B Gazzard6, N Obel7, P Vernazza8, Z Fox5, J D Lundgren5, and on behalf of the MaxCmin 2 Trial Group
1Univ. of Toronto, Canada; 2FUNDAI, Buenos Aires, Argentina; 3Brookdale Univ. Hosp., Brooklyn, NY, USA; 4Ctr. Hosp. Univ. Sainte-Pierre, Brussels, Belgium; 5Hvidovre Univ. Hosp., Copenhagen, Denmark; 6Chelsea and Westminster Healthcare Trust, London, UK; 7Odense Univ. Hosp., Denmark; and 8Kantonsspital, St Gallen, Switzerland
E Martinez*1, A Milinkovic1, P Domingo2, M C Gomila2, S Vidal1, R Casamitjana1, M Larrouse1, J L Blanco1, J Mallolas1, F Garcia1, J M Miro1, and J M Gatell1
1Hosp. Clin., Barcelona, Spain and 2Hosp. de Sant Pau, Barcelona, Spain
M Noor1, C Dezii*1, C McLaren2, V Wirtz2, J Maa1, L Bessen3, and S Hodder1
1Bristol-Myers Squibb, Virology Med. Affairs, Plainsboro, NJ, USA; 2Bristol-Myers Squibb Pharm. Res. Inst., Wallingford, CT, NJ, USA; and 3Bristol-Myers Squibb Pharm. Res. Inst., Princeton, NJ, USA
J A Aberg1, R A Zackin*2, S R Evans2, Y Yang2, B L Alston3, W K Henry4, M J Glesby5, SW Brobst3, S I Owens6, C J Fichtenbaum7, and ACTG 5087 Team
1Washington Univ., St. Louis, MO, USA; 2Harvard Sch. of Publ. Hlth., Boston, MA, USA; 3NIAID, NIH, DHHS, Bethesda, MD, USA; 4Univ. of Minnesota, Minneapolis, USA; 5Cornell Univ., New York, NY, USA; 6Frontier Sci. and Technology Res. Fndn., Amherst, NY, USA; and 7Univ. of Cincinnati, OH, USA
D A Wohl*, C Cunningham, H-C Tien, B McIntosh, K Donovan, S-Y Leu, and R J Simpson Jr
Univ. of North Carolina at Chapel Hill, USA
U R Hengge*1, K Stocks2, S Faulkner3, H Wiehler2, C Lorenz4, W Jentzen5, A Mirmohammadsadegh6, D Hengge7, and G Ringham3
1Univ. of Düsseldorf, Germany; 2Univ. of Essen STD Unit, Germany; 3Unimed Pharm. Inc., Deerfield, IL, USA; 4Hosp. Pharmacy, Univ. of Essen, Essen, Germany; 5Univ. of Essen, Germany; 6Joachim Kuhlmann AIDS Fndn., Essen, Germany; and 7Univ. of Bonn, Germany
M Lafaurie, M Dolivo, D Boulu, H Finel, R Porcher, I Madelaine, A Furco, J Pavie, N Decastro, and J M Molina*
Saint Louis Hosp., Paris, France
D Carey*1, H Wand1, A Martin1, S Emery1, A Carr2, D Cooper1,2, and the ROSEY Study Group
1Univ. of New South Wales, Sydney, Australia and 2St. Vincent's Hosp., Sydney, Australia
